Giuseppe D. R.

Addresses both Non‑Small Cell Lung Cancer and Small Cell Lung Cancer with emphasis on molecularly defined subgroups.

• EGFR‑mutated NSCLC after tyrosine‑kinase inhibitor failure
• ALK‑positive NSCLC
• Second‑line treatment for extensive‑stage SCLC

Therapeutic focus includes targeted agents, immunotherapy combinations and strategies for brain‑metastatic disease.

Encompasses malignancies of the digestive tract, highlighting endoscopic assessment and systemic therapy integration.

• Metastatic colorectal cancer with KRAS G12C mutation
• HER2‑low gastric and gastro‑esophageal junction adenocarcinoma
• Neuroendocrine tumors of the pancreas and gastrointestinal tract

Efforts target molecularly guided treatments, antibody‑drug conjugates and peptide‑receptor radionuclide therapy.

Focuses on malignancies of the kidney, prostate and urinary tract, integrating systemic and localized approaches.

• Clear‑cell renal cell carcinoma with intermediate‑risk features
• Metastatic castration‑resistant prostate cancer with PSMA expression
• Urothelial carcinoma refractory to checkpoint inhibition

Research prioritizes novel tyrosine‑kinase inhibitors, radioligand therapy and combination immuno‑oncology regimens.

Explores both acute leukemias and lymphoid neoplasms, emphasizing molecular risk stratification.

• Acute myeloid leukemia with NPM1 mutation
• Philadelphia‑negative acute lymphoblastic leukemia
• Diffuse large B‑cell lymphoma relapsed after CAR‑T therapy

Therapeutic avenues include targeted inhibitors, bispecific antibodies and post‑transplant maintenance strategies.